Marksans Pharma Ltd. has officially announced that its Board of Directors will convene on Tuesday, May 26, 2026. The primary agenda for the meeting includes the review and approval of the company’s audited financial results for the quarter and fiscal year ending March 31, 2026. Additionally, the Board will deliberate on a potential dividend recommendation for equity shareholders for the 2025-26 financial year.
Upcoming Board Meeting Details
The management of Marksans Pharma Ltd. has scheduled a board meeting to evaluate the company’s performance for the period concluding on March 31, 2026. During this session, the directors will review the audited financial results on both a standalone and consolidated basis to assess the company’s growth and operational health for the fiscal year.
Dividend Considerations
Beyond the financial reporting, the Board of Directors is set to discuss and potentially recommend a dividend payout for the 2025-26 financial year. This decision remains subject to final approval, and shareholders will be updated on any confirmed distribution following the conclusion of the meeting.
Trading Window Restrictions
In accordance with internal compliance protocols, the company has restricted trading activities for designated persons and their immediate relatives. This trading window closure commenced on April 01, 2026, and will remain in effect until 48 hours following the official public announcement of the financial results, specifically through May 28, 2026.
Source: BSE
